AwardTape · Defense awards · Sofie Co
Sofie Co: $2.9M in DoD and DHS awards
Sofie Co holds 32 DoD and DHS prime awards with $2.9M obligated Oct 23, 2023 to Jun 4, 2026. Largest category: Drugs and biologicals at $2.8M; largest buyer: Defense Health Agency at $2.4M.
| Obligated FY2024+ | $2.9M |
|---|---|
| Awards | 32 |
| FY2024 | $946K |
| FY2025 | $1.2M |
| FY2026 to date | $776K |
| Lifetime obligated on these awards | $3.2M |
| Parent company (as reported) | Sofie Co |
| First and latest action | Oct 23, 2023 · Jun 4, 2026 |
By categoryObligated FY2024+
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Drugs and biologicals | $2.8M | 24 awards | 97% |
| 2 | Health care services | $58K | 3 awards | 2.0% |
| 3 | Instruments and lab equipment | $25K | 1 awards | 0.9% |
| 4 | Medical equipment and supplies | $8.7K | 4 awards | 0.3% |
By agencyObligated FY2024+
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Defense Health Agency | $2.4M | 27 awards | 83% |
| 2 | Department of the Army | $485K | 5 awards | 17% |
Largest awards50 per page · sorted by obligated
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| HT001426FE014 BPA call | $250K | Bpa call order for radioactive pharmaceuticals required for positron emission tomography (pet). | Defense Health Agency | Drugs and biologicals | Jan 7, 2026 DoD 90d |
| HT001424F0057 BPA call | $249K | Life molecular imaging product neurace | Defense Health Agency | Drugs and biologicals | May 15, 2024 DoD 90d |
| HT001424F0118 BPA call | $249K | Life molecular imaging product | Defense Health Agency | Drugs and biologicals | Jul 26, 2024 DoD 90d |
| HT001425F0019 BPA call | $249K | Radiopharmaceuticals | Defense Health Agency | Drugs and biologicals | Jan 15, 2025 DoD 90d |
| HT001423P0165 purchase order | $249K | Pyl-c pylarify f-18 piflufolastat | Defense Health Agency | Drugs and biologicals | Jan 19, 2024 DoD 90d |
| HT001425F0044 BPA call | $249K | Neuraceq radiopharmaceutical for positron emission tomography scans | Defense Health Agency | Drugs and biologicals | May 1, 2025 DoD 90d |
| HT001425F0050 BPA call | $246K | Pylarify f 18 injection for pet scan imaging of the prostate. | Defense Health Agency | Drugs and biologicals | Apr 18, 2025 DoD 90d |
| HT001426FE062 BPA call | $245K | Acquisition of neuraceq (florbetaben f18). | Defense Health Agency | Drugs and biologicals | Jun 4, 2026 DoD 90d |
| W81K0024F0075 BPA call | $197K | Various radiopharmacueticals | Army | Drugs and biologicals | Nov 7, 2024 DoD 90d |
| W81K0025PA260 purchase order | $188K | Radiopharmaceuticals requirement is necessary to support the department of radiology, nuclear medicine clinic. | Army | Drugs and biologicals | Dec 18, 2025 DoD 90d |
| W81K0023F0141 BPA call | $100K | Radiopharmaceuticals for bamc | Army | Drugs and biologicals | Jul 23, 2024 DoD 90d |
| HT009025FG0610064 BPA call | $44K | Radio-pharmaceuticals | Defense Health Agency | Drugs and biologicals | May 27, 2025 DoD 90d |
| HT009025FG081100 BPA call | $44K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment sofie (s0f-neuraceq) | Defense Health Agency | Drugs and biologicals | Jul 23, 2025 DoD 90d |
| HT009024FG0910085 BPA call | $36K | Radiopharmaceutical. | Defense Health Agency | Drugs and biologicals | Sep 9, 2024 DoD 90d |
| HT009026FG1110036 BPA call | $36K | Pharmaceuticals needed for patient care. | Defense Health Agency | Drugs and biologicals | Nov 4, 2025 DoD 90d |
| HT009024FG0510058 BPA call | $32K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment | Defense Health Agency | Drugs and biologicals | May 21, 2024 DoD 90d |
| HT009025FG0310056 BPA call | $29K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment | Defense Health Agency | Health care services | Mar 20, 2025 DoD 90d |
| HT009025FG0310051 BPA call | $25K | "radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment. | Defense Health Agency | Drugs and biologicals | Mar 5, 2025 DoD 90d |
| HT009025FG1210047 BPA call | $25K | Radiopharmaceutical needed for prostate cancer patients with metastatic lesions after definite treatment | Defense Health Agency | Drugs and biologicals | Dec 19, 2024 DoD 90d |
| HT009026FG1210062 BPA call | $25K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment | Defense Health Agency | Instruments and lab equipment | Dec 2, 2025 DoD 90d |
| HT009026FG0210049 BPA call | $22K | Radio-pharmaceutical for patient care. | Defense Health Agency | Drugs and biologicals | Feb 4, 2026 DoD 90d |
| HT009025FG0210044 BPA call | $22K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment | Defense Health Agency | Drugs and biologicals | Feb 10, 2025 DoD 90d |
| HT009025FG0710073 BPA call | $14K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment | Defense Health Agency | Health care services | Jun 24, 2025 DoD 90d |
| HT009025FG0820120 BPA call | $14K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definite treatment | Defense Health Agency | Health care services | Aug 20, 2025 DoD 90d |
| HT009024FG0510042 BPA call | $11K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment | Defense Health Agency | Drugs and biologicals | May 9, 2024 DoD 90d |
| HT009024FG0610050 delivery order | $11K | Radiopharmaceutical needed for prostate cancer patient with metastatic lesions after definitive treatment. | Defense Health Agency | Drugs and biologicals | Jun 26, 2024 DoD 90d |
| HT009024FG0810071 BPA call | $11K | Radiopharmaceutical required for patient care. | Defense Health Agency | Medical equipment and supplies | Aug 13, 2024 DoD 90d |
| HT009026FG0110043 BPA call | $11K | Radiopharmaceutical needed for prostate cancer patient. | Defense Health Agency | Drugs and biologicals | Dec 26, 2025 DoD 90d |
| HT001424A0002 blanket purchase agreement | $0 | Master blanket purchase agreement for pharmaceutical supplies. | Defense Health Agency | Drugs and biologicals | Dec 23, 2025 DoD 90d |
| W81K0020A0016 blanket purchase agreement | $0 | Provide radiopharmaceutical to mtfs | Army | Medical equipment and supplies | Oct 23, 2023 DoD 90d |
| W81K0023F0091 BPA call | $0 | Radiopharmaceuticals | Army | Medical equipment and supplies | Feb 13, 2024 DoD 90d |
| HT001421P0008 purchase order | -$2.1K | The requirement of f-18 "neuraceq", is a nuclear medicine pet use to imaging the brain to estimate amyloid neuritic plaque density in adult patients at walter reed national military medical center. | Defense Health Agency | Medical equipment and supplies | Jul 25, 2024 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial